University of Washington

University of California

Institute for Research in Biomedicine

Emerald Biostructures, Incorporated

San Diego State University Research Foundation

Lance Joseph Stewart

David Baker

Neil P King

Antonio Lanzavecchia

Justin Bloomfield Siegel

Ingrid Swanson Pultz

Hidong Kim

Christine Elaine Tinberg

Jessica Marcandalli

Peter Nollert

Laurent Perez

Clancey Wolf

Brooke Fiala

Jorge Fallas

Daniel Adriano Silva Manzano

Daniel Ellis

Deborah Fuller

Michael David Feese

George Ueda

Lauren Carter

Yang Hsia

Aaron Arthur Chevalier

Merika Treants Koday

Mark B Mixon

Gabriel Jacob Rocklin

Christopher David Bahl

Brooke Nickerson

Jason Gilmore

Sridhar Prasad

Alex B Burgin, Jr

Rashmi Ravichandran

Una Nattermann

Disclosed herein are nanostructures and their use, where the nanostructures include

Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use

Nanostructures and nanostructure-based vaccines that display antigens capable of eliciting immune responses to infectious agents such as bacteria, viruses, and pathogens are provided. Some vaccines are useful for preventing or decreasing the severity of infection with an infectious agent, including, for example and without limitation, lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens may be attached to the core of the nanostructure either non-covalently or covalently, including as a fusion protein or by other means. Multimeric antigens may optionally be displayed along a symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

Self-asssembling nanostructure vaccines

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructures; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and/or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, are provided, wherein (a) the polypeptide degrades a PFQFQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.

Compositions and methods for treating celiac sprue disease

Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO:1, are provided, wherein (a) the polypeptide degrades a PFQPQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.

Polypeptides, and methods for their use, are disclosed that have an amino acid sequence at least 75% identical to the amino acid sequence of SEQ ID NO: 1, are provided, wherein (a) the polypeptide degrades a PFQPQLPY (SEQ ID NO: 140) peptide and/or a PFPQPQQPF (SEQ ID NO: 68) at pH 4; (b) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp; and (c) the polypeptide comprises an amino acid change from SEQ ID NO: 1 at one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E/Q/R/Y, 358S/Q/T, 368F/Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456.

Polypeptides that bind to viral hemagglotinin are disclosed and methods for their use in treating or limiting influenza infection, and diagnosing influenza infection.

De novo designed hemagglutinin binding proteins

A coupling system can utilize a first receptacle and a second receptacle to couple syringes together. Syringes can be used to mix viscous material and/or dispense the viscous material. Furthermore, a kit can be provided that contains parts used in mixing and/or dispensing viscous material.

Method and apparatus for preparing lipidic mesophase material

This invention encompasses an apparatus for creating a database containing the results of distributed molecular replacement searches, which comprise data input system for inputting the results of distributed molecular replacement searches and related information and a database generator coupled to said data input system for receiving the results of distributed molecular replacement searches and related information and creating a database for storing the results of distributed molecular replacement searches and related information. The invention includes method of managing the invention of distributed molecular replacement searches.

[object Object]

The invention provides a method of nonenzymatic ligation of a nucleic acid. The method consists of contacting a polynucleotide-3' phosphorothiolate with an acceptor polynucleotide under conditions that allow formation of a phosphodiester bond between the polynucleotide-3&#x2032; phosphorothiolate and the acceptor polynucleotide. The invention also provides methods of molecular cloning. In one embodiment, the method consists of contacting an insert comprising a polynucleotide-3&#x2032; phosphorothiolate with an acceptor vector under conditions that allow formation of a phosphodiester bond between the insert and the acceptor vector to generate a vector comprising an insert polynucleotide. The invention further provides a compound consisting of a polynucleotide-3&#x2032; phosphorothiolate and a kit containing a polynucleotide-3&#x2032; phosphorothiolate. Also provided is a method of ligating a nucleic acid using a non-sequence specific topoisomerase.

Use of phosphorothiolate polynucleotides in ligating nucleic acids

Growing community of inventors

Seattle, WA, United States of America

Lance Joseph Stewart